Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2015
This article has no abstract
Epistemonikos ID: 93061db1cc56bcfb5b209035d6c17a6cb4c65b0e
First added on: Apr 17, 2025